Skinvisible Reports Q1 2026 Financial Results with Decreased Net Loss and Stable Revenue

Skinvisible, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $267,184, a decrease from the net loss of $281,005 recorded in the same period of 2025. The company's revenue remained stable at $5,000 for both quarters, with no cost of revenues reported, resulting in a consistent gross profit of $5,000. Operating expenses decreased to $130,938 from $144,852 year-over-year, primarily due to reduced selling, general, and administrative costs. The company continues to face significant financial challenges, with cumulative net losses totaling $41,277,360 since its inception.

In terms of financial position, Skinvisible's total assets decreased to $119,419 as of March 31, 2026, down from $127,567 at the end of 2025. Current liabilities increased to $5,276,981 from $5,017,945, contributing to a working capital deficit of $5,252,591. The company reported cash and cash equivalents of $1,798, a decline from $2,620 at the end of the previous fiscal year. The management has expressed concerns regarding the company's ability to continue as a going concern, emphasizing the need for additional capital to support operational and marketing activities.

Strategically, Skinvisible is focused on leveraging its patented polymer delivery system, Invisicare, to enhance the efficacy of topical products. The company has developed over forty formulations and is actively pursuing licensing agreements with pharmaceutical and consumer goods companies. Recent developments include a license agreement with Quoin Pharmaceuticals for the product QRX003, which is undergoing clinical trials for Netherton Syndrome. The company is optimistic about potential revenue generation from these licensing agreements and aims to expand its market presence.

Operationally, Skinvisible has maintained its customer base and is exploring new opportunities in the skincare and dermatology markets, which are estimated to be worth $80 billion globally. The company is also investigating applications of its technology in other medical fields, such as obesity management. Despite the challenges, management remains committed to enhancing product adoption rates and expanding geographic reach through strategic partnerships.

Looking ahead, Skinvisible plans to seek additional financing through private equity offerings to support its operations and growth initiatives. The company is also focused on improving its internal controls and financial reporting processes, which have been identified as areas needing enhancement. Management's ability to secure funding and successfully execute its business strategy will be critical for the company's future viability and potential return to profitability.